Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:BDTX NASDAQ:RANI NASDAQ:RKTO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.67$0.85$0.61▼$10.38$93.62M1.711.36 million shs2.02 million shsBDTXBlack Diamond Therapeutics$1.66$2.54$1.62▼$4.94$95.12M3.222.02 million shs1.91 million shsRANIRani Therapeutics$0.78$0.91$0.39▼$3.87$96.92M0.74915,570 shs303,043 shsRKTORocket One Inc. Common Stock$1.08$0.95$0.49▼$2.45$24.11M0.8921.93 million shs1.88 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma+5.87%+1.22%-22.16%-51.31%-92.69%BDTXBlack Diamond Therapeutics-0.60%-8.79%-44.67%-21.33%-28.76%RANIRani Therapeutics+2.25%-2.44%-11.53%-30.76%+54.02%RKTORocket One Inc. Common Stock-1.82%-27.03%+80.00%+18.08%-19.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.67$0.85$0.61▼$10.38$93.62M1.711.36 million shs2.02 million shsBDTXBlack Diamond Therapeutics$1.66$2.54$1.62▼$4.94$95.12M3.222.02 million shs1.91 million shsRANIRani Therapeutics$0.78$0.91$0.39▼$3.87$96.92M0.74915,570 shs303,043 shsRKTORocket One Inc. Common Stock$1.08$0.95$0.49▼$2.45$24.11M0.8921.93 million shs1.88 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma+5.87%+1.22%-22.16%-51.31%-92.69%BDTXBlack Diamond Therapeutics-0.60%-8.79%-44.67%-21.33%-28.76%RANIRani Therapeutics+2.25%-2.44%-11.53%-30.76%+54.02%RKTORocket One Inc. Common Stock-1.82%-27.03%+80.00%+18.08%-19.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/ABDTXBlack Diamond Therapeutics 2.73Moderate Buy$10.00502.41% UpsideRANIRani Therapeutics 2.60Moderate Buy$8.751,018.35% UpsideRKTORocket One Inc. Common Stock 2.00Hold$5.00362.96% UpsideCurrent Analyst Ratings BreakdownLatest RKTO, BDTX, AIFC, and RANI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026RKTORocket One Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.004/24/2026RKTORocket One Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/23/2026BDTXBlack Diamond Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M3.77N/AN/A$9.07 per share0.07BDTXBlack Diamond Therapeutics$70M1.36$0.52 per share3.17$1.97 per share0.84RANIRani Therapeutics$1.63M59.46N/AN/A$0.34 per share2.30RKTORocket One Inc. Common StockN/AN/AN/AN/A$0.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-2,483.94%-68.25%-62.43%N/ABDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)RANIRani Therapeutics-$29.67M-$0.41N/AN/AN/AN/A-206.46%-83.95%8/6/2026 (Estimated)RKTORocket One Inc. Common Stock-$12.47M-$0.80N/AN/AN/AN/A-165.25%-143.61%9/2/2026 (Estimated)Latest RKTO, BDTX, AIFC, and RANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026AIFCALT5 SigmaN/A-$2.14N/A-$2.14N/A$4.71 million5/15/2026Q1 2026RANIRani Therapeutics-$0.06-$0.04+$0.02-$0.04$1.13 million$1.71 million5/15/2026Q1 2026RKTORocket One Inc. Common Stock-$0.1378-$0.17-$0.0322-$0.17N/AN/A5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 million3/27/2026Q4 2025RKTORocket One Inc. Common Stock-$0.1031-$0.16-$0.0569-$0.16N/AN/A3/26/2026Q4 2025RANIRani Therapeutics-$0.03-$0.07-$0.04-$0.07$5.00 million$1.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/ABDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ARKTORocket One Inc. Common StockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.030.820.82BDTXBlack Diamond TherapeuticsN/A8.468.46RANIRani TherapeuticsN/A3.403.40RKTORocket One Inc. Common StockN/A3.393.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%BDTXBlack Diamond Therapeutics95.47%RANIRani Therapeutics30.19%RKTORocket One Inc. Common Stock7.08%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%BDTXBlack Diamond Therapeutics9.29%RANIRani Therapeutics26.73%RKTORocket One Inc. Common Stock6.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170139.84 million139.54 millionN/ABDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableRANIRani Therapeutics110123.88 million90.77 millionOptionableRKTORocket One Inc. Common Stock422.32 million20.78 millionNot OptionableRKTO, BDTX, AIFC, and RANI HeadlinesRecent News About These CompaniesRocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense MarketsJune 15, 2026 | prnewswire.comSpace Stocks Get Torched: Short Seller Calls Them 'Sci-Fi Wishes'June 12, 2026 | benzinga.comRocket One (RKTO) stock is trending after hours as retired NASA astronaut joins advisory board: Here's what you need to knowJune 12, 2026 | msn.comZentalis Pharmaceuticals (NASDAQ:ZNTL) vs. Rocket One Inc. Common Stock (NASDAQ:RKTO) Head to Head SurveyJune 12, 2026 | americanbankingnews.comROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.June 3, 2026 | prnewswire.comRKTO Rocket One Inc.May 30, 2026 | seekingalpha.comRocket One Inc.May 30, 2026 | cnn.comFrom biotech to orbit: Rocket One's AI and space re-brand sends shares flyingMay 29, 2026 | msn.comRocket One Rebrands From Hoth, Refocusing on Space ComputingMay 28, 2026 | theglobeandmail.comRKTO Stock Extends Rally After Landing Its First AI Catalyst – Retail Bulls Are Chasing An AI-Space DreamMay 28, 2026 | finance.yahoo.comHoth Therapeutics’ pivot to AI in space sees stock rocket after rebrandMay 28, 2026 | fiercebiotech.comFHoth Therapeutics, Inc.: Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra ...May 27, 2026 | finanznachrichten.deHoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation ...May 27, 2026 | tmcnet.comRocket One Rebrand Marks Strategic Shift Toward Space AI Chip and Orbital Computing Markets (RKTO)May 27, 2026 | finance.yahoo.comHOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh DealsMay 27, 2026 | finance.yahoo.comHoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense ApplicationsMay 27, 2026 | prnewswire.comHoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology PlatformMay 26, 2026 | prnewswire.comHoth Therapeutics, Inc.: AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of ...May 20, 2026 | finanznachrichten.deHoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH)May 20, 2026 | msn.comAI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor ArchitectureMay 19, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRKTO, BDTX, AIFC, and RANI Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.67 0.00 (0.00%) As of 06/18/2026 04:00 PM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Black Diamond Therapeutics NASDAQ:BDTX$1.66 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.67 +0.01 (+0.60%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Rani Therapeutics NASDAQ:RANI$0.78 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.78 0.00 (-0.18%) As of 06/18/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Rocket One Inc. Common Stock NASDAQ:RKTO$1.08 0.00 (0.00%) As of 06/18/2026 04:00 PM EasternHoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
